Cagrilintide Tre - 5MG

Log in to view pricing Apply for provider account
Cagrilintide Tre - 5MG
Availability:
In Stock

Product Overview

Cagrilintide Tre

Cagrilintide Tre is a long-acting, lipidated amylin analogue and dual amylin & calcitonin receptor agonist (DACRA) with affinity for AMY1R/AMY2R/AMY3R and the calcitonin receptor. It is in clinical development for chronic weight management and type 2 diabetes, including fixed-dose combination with semaglutide (CagriSema).[1,2,5–9,11]

Mechanism of Action

  • Acts centrally at brain amylin receptors—especially AMY1R and AMY3R—to reduce food intake and body weight.[4]
  • Adopts a “bypass” binding pose enabling non-selective activation of Gs signaling via both amylin and calcitonin receptors; receptor balance contributes to potent weight effects.[3,5,10]
  • Novel design (AM833/cagrilintide lineage) provides extended half-life for once-weekly dosing.[1,5,9]

Clinical Efficacy

  • Monotherapy (Phase 2): Once-weekly 0.3–4.5 mg produced dose-dependent mean weight loss of ~6.0–10.8% at 26 weeks; 4.5 mg surpassed liraglutide 3.0 mg (10.8% vs 9.0%, p=0.03). Predominant fat-mass reduction with metabolic improvements.[11]
  • Combination with Semaglutide (Phase 1b/2): Co-administered cagrilintide+semaglutide 2.4 mg yielded mean weight loss ~15.4–17.1% at 20–32 weeks—greater than either alone.[9,8]
  • CagriSema in T2D (Phase 2): In adults with overweight/obesity and T2D, fixed-dose cagrilintide+semaglutide (each 2.4 mg) achieved mean weight loss ~15.6% at 32 weeks with HbA1c reduction ~−2.2%, outperforming monotherapies.[7,2]

Safety & Tolerability

  • Generally well tolerated; most common events are mild–moderate GI symptoms (nausea, constipation, diarrhea) and injection-site reactions; discontinuation ~4–5%.[11,8,9]
  • No excess hypoglycemia observed, including with background sulfonylureas.[11]
  • Safety profile aligns with incretin-based anti-obesity/diabetes therapies.[8,9]

Clinical Implications

  • Promising adjunct to lifestyle for chronic weight management with/without T2D.[11]
  • CagriSema provides additive benefits for weight and glycemic control; ongoing Phase 3 to refine role in care pathways.[2,7,8]
  • Dual amylin/calcitonin receptor engagement and prolonged exposure distinguish cagrilintide from prior amylin analogues and other DACRAs.[1,5,10]

References

  1. Kruse T, Hansen JL, Dahl K, et al. J Med Chem. 2021;64(15):11183-11194. doi:10.1021/acs.jmedchem.1c00565.[1]
  2. Garvey WT, Blüher M, Osorto Contreras CK, et al. NEJM. 2025;393(7):635-647. doi:10.1056/NEJMoa2502081.[2]
  3. Gu YM, Yuan QN, Li X, et al. Acta Pharmacol Sin. 2025. doi:10.1038/s41401-025-01635-2.[3]
  4. Carvas AO, Leuthardt A, Kulka P, et al. EBioMedicine. 2025;118:105836. doi:10.1016/j.ebiom.2025.105836.[4]
  5. Fletcher MM, Keov P, Truong TT, et al. J Pharmacol Exp Ther. 2021;377(3):417-440. doi:10.1124/jpet.121.000567.[5]
  6. Gabery S, Glendorf T, Ballarin-Gonzalez B, et al. Life Sci. 2025;378:123845. doi:10.1016/j.lfs.2025.123845.[6]
  7. Davies MJ, Bajaj HS, Broholm C, et al. NEJM. 2025;393(7):648-659. doi:10.1056/NEJMoa2502082.[7]
  8. Frias JP, Deenadayalan S, Erichsen L, et al. Lancet. 2023;402(10403):720-730. doi:10.1016/S0140-6736(23)01163-7.[8]
  9. Enebo LB, Berthelsen KK, Kankam M, et al. Lancet. 2021;397(10286):1736-1748. doi:10.1016/S0140-6736(21)00845-X.[9]
  10. Larsen AT, Mohamed KE, Sonne N, et al. Biomed Pharmacother. 2022;156:113842. doi:10.1016/j.biopha.2022.113842.[10]
  11. Lau DCW, Erichsen L, Francisco AM, et al. Lancet. 2021;398(10317):2160-2172. doi:10.1016/S0140-6736(21)01751-7.[11]

All information provided is for research purposes only.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY. The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.